110 results
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
, including but not limited to failed studies, complex results, safety issues, or other regulatory challenges.
We expect that our existing cash … Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
15 May 24
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
-term safety and efficacy data from the Phase 2 portion of the Orbit study are expected in the second half of 2024.
The Cosmic study was initiated … product candidates in clinical development. Etigilimab (anti-TIGIT) has completed a Phase 1b/2 basket study evaluating its safety and efficacy
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
which time he was involved in the safety and efficacy review of hundreds of drugs. Most recently Dr. Shames served as Deputy Director, Office of Drug
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
efficacy, safety, patent and regulatory exclusivity, anticipated or approved labeling, present and future market potential, competitive market conditions … . Halting enrolment due to a safety issue or request by a Regulatory Authority will not be considered to be Completion of Enrolment;
“Confidential
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
for leflutrozole for the treatment of HH and in December 2018, we reported positive results from the safety extension study for leflutrozole. In December 2023 we … . There were no cardiac-related safety concerns observed in the study.
Top-line Data from Setrusumab Phase 2 Portion of Phase 2/3 Orbit Study
In June
8-K
EX-99.1
pyaapw3r ltnxd
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
8-K
EX-99.1
qufk 5foo55o4ht1uq
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
6-K
EX-3.1
6z9e79
18 Dec 23
Current report (foreign)
4:10pm
6-K
EX-99.1
j21lycd sfo
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
6-K
EX-99.1
c9ugen6 m19d3jvaft
17 Oct 23
Current report (foreign)
7:01am
6-K
nrdu8i
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.3
y8dh9f4rm9z2x91nh4z
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.2
1qgr4qniabqjqf
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
f691ritbx8
6 Jul 23
Ultragenyx Announces First Patients Dosed in Phase 3 Program
8:05am
6-K
EX-99.1
4zmuasap5
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.1
i9685k9
8 May 23
Current report (foreign)
4:07pm
6-K
EX-99.1
8sn1 eade8ja8
5 May 23
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5:06pm
6-K
EX-99.2
5yry72ve1v fr
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.2
0t1stk3uc5g7usvp1bkf
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
zipknwzkjr p7p
17 Oct 22
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of
7:16am